Which treatment regimen can I prescribe for latent tuberculosis infection in an adult without liver disease, pregnancy, or known drug interactions?

Treatment Recommendation for Latent Tuberculosis Infection

For an adult without liver disease, pregnancy, or drug interactions, prescribe 3 months of once-weekly isoniazid plus rifapentine (3HP) as the preferred first-line regimen 1.

Preferred Treatment Options (in order of priority)

The 2020 CDC/NTCA guidelines establish a clear hierarchy of treatment regimens 1:

First-Line Preferred Regimens:

1. 3 months of isoniazid plus rifapentine given once weekly (3HP) - Strong recommendation with moderate evidence 1

   • Highest completion rates among all regimens
   • Excellent tolerability and efficacy
   • Shortest treatment duration
   • Most recent research confirms significantly higher completion rates (97.8%) compared to traditional isoniazid monotherapy 2

2. 4 months of daily rifampin (4R) - Strong recommendation with moderate evidence in HIV-negative patients 1

   • Excellent alternative when rifapentine unavailable
   • Lower hepatotoxicity than isoniazid-based regimens
   • Higher completion rates than longer regimens

3. 3 months of daily isoniazid plus rifampin (3HR) - Conditional recommendation 1

   • Very low quality evidence in HIV-negative patients
   • Network meta-analysis shows efficacy comparable to longer isoniazid regimens 3
   • Significantly reduces TB incidence (34% adherence improvement) 4

Alternative Regimens (when preferred regimens cannot be used):

• 6 months of daily isoniazid (6H) - Strong recommendation with moderate evidence 1
• 9 months of daily isoniazid (9H) - Conditional recommendation with moderate evidence 1

Key Clinical Considerations

Why 3HP is Preferred:

The once-weekly 3HP regimen demonstrates superior real-world effectiveness due to:

• Completion rates approaching 98% in recent cohort studies 2
• Significantly lower hepatotoxicity (4.6% vs 32.9% with 6-month isoniazid) 2
• Shorter duration improves adherence and reduces treatment fatigue
• Comparable efficacy to longer regimens in preventing active TB 3

Important Caveats:

Drug interactions: While your patient has no known drug interactions, be aware that rifamycins interact with:

• Warfarin
• Oral contraceptives
• Azole antifungals
• HIV antiretroviral therapy 1

Hepatotoxicity monitoring: Although your patient has no liver disease, baseline and periodic liver function testing is prudent, particularly with:

• 9H regimen (highest risk of grade 3-4 hepatotoxicity) 4
• 6H regimen (32.9% relevant hepatotoxicity in recent studies) 2
• 3HP and 3HR regimens (lower but still present risk)

Common Pitfalls to Avoid:

1. Don't default to 9-month isoniazid - Despite historical use, it has lower completion rates (67.6%) and higher hepatotoxicity than rifamycin-based regimens 2

2. Don't overlook treatment completion - Effectiveness depends on completion, not just efficacy. The 3HP regimen's shorter duration translates to better real-world outcomes 1

3. Don't ignore patient preference - Discuss once-weekly supervised dosing (3HP) versus daily self-administered options (4R, 3HR) based on patient lifestyle and reliability

Practical Implementation

For your patient, prescribe:

• Isoniazid 900 mg + Rifapentine 900 mg once weekly for 12 weeks (3HP)
• Consider directly observed therapy or virtual monitoring for the 12 doses
• Baseline liver function tests recommended
• Monitor for adverse effects at weeks 2,4, and 8

If 3HP is unavailable or not tolerated:

• Second choice: Rifampin 600 mg daily for 4 months (4R)
• Third choice: Isoniazid 300 mg + Rifampin 600 mg daily for 3 months (3HR)

The evidence strongly supports moving away from traditional 6-9 month isoniazid monotherapy toward shorter rifamycin-based regimens that balance efficacy with real-world completion rates 1, 2, 3.